Navigation Links
Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2008
Date:10/21/2008

CALGARY, Oct. 21 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 7th Annual BIO Investor Forum 2008 on Wednesday, October 29, 2008 at 2:15 p.m. PT. The conference will be held at the Palace Hotel in San Francisco from October 29-31, 2008.

A live audio link to the webcast presentation is available at: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=ONC.TO&item_id=1996001, or on the company's website at http://www.oncolyticsbiotech.com. It is recommended that listeners log on 15 minutes in advance of the presentation to register and download any necessary software.

An audio replay will be accessible approximately one hour following the presentation on the Oncolytics website.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

The presentation and webcast times are subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Six Sigma and Social Media: Tools for Reducing Costs, Improving Processes
2. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
3. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
4. Cell Therapeutics Provides Details on Investor & Media Day to be Held in Milan, Italy on Friday, October 3, 2008
5. Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
6. U.S. News Media Group Releases 19th Edition of Americas Best Hospitals
7. VIDEO from Medialink and Med-El: New Technology is Music to Peoples Ears
8. BioLife Solutions Announces FDA Master File Acceptance for CryoStor(TM) Pre-formulated Cryopreservation Media
9. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
10. Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008
11. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... As Ebola resurfaces in the Democratic Republic of ... now reported, a new analysis of the Ebola gene polymerase ... the 2014 and 2017 outbreaks of the disease.  ... preceded the 2014 outbreak. An analysis of the latest data ... 2014-15, which again precedes the current outbreak in the DRC. ...
(Date:5/23/2017)... , ... May 23, 2017 , ... A recent survey ... most troublesome and difficult to control weed in 12 categories of broadleaf crops, fruits ... 200 weed scientists across the U.S. and Canada participated in the 2016 survey, the ...
(Date:5/23/2017)... Basel, Switzerland (PRWEB) , ... May 23, 2017 ... ... for R&D, celebrates this month its 20th anniversary, marking the occasion with a ... is sponsoring the meeting’s Welcome Reception and further extends an invitation to all ...
(Date:5/23/2017)... BELLINGHAM, Washington, USA (PRWEB) , ... May 22, ... ... SPIE Optics and Photonics 2017 in San Diego, California, this August ... virtual reality, solar fuels, and autonomous vehicles. , SPIE Optics and Photonics, the ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... Report on Form 10-K on Thursday April 13, 2017 with the ... The ... section of the Company,s website at http://www.nxt-id.com  under "SEC Filings," ... 2016 Year Highlights: Acquisition of ...
(Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
Breaking Biology News(10 mins):